Diabetes HCP Perception Study India: Treatment Trends, GLP-1 Therapies and Digital Health

Diabetes HCP Perception Study India: Treatment Trends, GLP-1 Therapies and Digital Health

Introduction

India's diabetes care landscape is evolving as therapeutic innovation, personalized treatment, and digital health technologies reshape clinical practice. However, unmet clinical needs, treatment adherence, and affordability continue to influence how healthcare professionals approach diabetes patient management in India.

To understand these challenges, a Diabetes HCP Perception Study India assessed the views of 50 healthcare professionals (HCPs) on treatment innovation, cardiometabolic risk, glucose monitoring, obesity management, and the future of diabetes care.

This diabetes market research study among Indian HCPs provides insights into clinical priorities, adoption barriers, and emerging opportunities for pharmaceutical, biotechnology, and MedTech companies. The findings offer a snapshot of HCP perceptions of diabetes treatment in India and highlight areas where further innovation and improved access could support better patient outcomes.

1. Unmet Needs in Diabetes Care in India

The study found that 96% of respondents considered continued innovation in diabetes care highly or very highly important, while 70% viewed existing treatment options as only partially adequate.

These findings highlight persistent unmet needs in diabetes care in India, including challenges in achieving sustained glycemic control, improving adherence, managing comorbidities, and reducing long-term complications.

Although existing therapies remain essential, diabetes treatment trends in India increasingly emphasize comprehensive disease management rather than glucose control alone. Healthcare professionals must consider disease progression, cardiovascular risk, kidney function, weight management, and individual patient needs.

Key priorities identified by the study include:

• Improving glycemic control and long-term treatment adherence.
• Strengthening diabetes and obesity management.
• Addressing cardiovascular and renal outcomes in diabetes.
• Supporting earlier diagnosis and timely treatment intensification.
• Improving access to appropriate therapies and monitoring technologies.

For pharmaceutical companies, these priorities create opportunities to develop evidence-based treatment strategies and patient-support initiatives that address the practical challenges of diabetes management.

2. GLP-1 and GIP-Based Therapies Are Influencing Treatment Innovation

Among the surveyed HCPs, 44% identified GLP-1 and GIP-based therapies, alongside newer cardiometabolic approaches, as the most impactful recent therapeutic advancement.

This finding reflects the growing relevance of GLP-1 therapies and diabetes management in India, particularly as treatment discussions increasingly include weight reduction, metabolic health, and cardiovascular risk alongside glycemic outcomes.

GLP-1 receptor agonists and newer incretin-based treatments have expanded therapeutic options for eligible patients. Their clinical relevance depends on the specific medicine, patient characteristics, approved indications, and supporting evidence.

Healthcare professionals increasingly evaluate treatments based on several considerations:

• Glycemic efficacy and durability.
• Weight-management benefits.
• Cardiovascular and kidney-related benefits where demonstrated.
• Safety, tolerability, and treatment persistence.
• Patient preferences, availability, and affordability.

Companies such as Novo Nordisk and Eli Lilly have contributed to this therapeutic evolution through incretin-based medicines and clinical development programs addressing diabetes and obesity.

For life sciences organizations, understanding Indian doctors' perspectives on diabetes treatment innovation is important for medical education, evidence generation, product positioning, and market access planning.

3. Personalized Diabetes Treatment and Cardiorenal Metabolic Risk Management

The study found that 90% of respondents considered personalized treatment and risk-based management extremely or very important.

These findings reinforce the need for personalized and risk-based diabetes treatment approaches that reflect differences in disease duration, comorbidities, metabolic characteristics, and individual treatment goals.

Cardiorenal metabolic risk management is particularly important when diabetes coexists with cardiovascular disease, chronic kidney disease, or obesity. Treatment decisions should account for these conditions alongside glycemic targets and patient preferences.

For example, a patient with type 2 diabetes and established cardiovascular disease may have different treatment priorities from a patient whose primary concerns are weight management or persistent hyperglycemia. Patients with kidney disease may require additional consideration of kidney function and evidence-based treatment recommendations.

Personalized diabetes treatment can help align therapeutic decisions with individual needs, while supporting earlier intervention and more comprehensive complication prevention.

For pharmaceutical companies, healthcare professional perception studies can reveal which treatment outcomes influence prescribing decisions, which patient groups remain underserved, and where clinical education may be needed.

4. Continuous Glucose Monitoring, Digital Health and AI in Diabetes Management

The survey found that 78% of HCPs believed continuous glucose monitoring (CGM), digital health, and AI would likely or very likely influence diabetes management. Additionally, 88% expected wider adoption of newer therapies, monitoring tools, and technology-enabled care.

These findings point to growing interest in diabetes digital health solutions that complement traditional clinical consultations and support more informed treatment decisions.

CGM provides ongoing glucose readings and trends that can help appropriate patients and clinicians understand glucose variability. When used in suitable clinical settings, these insights can complement HbA1c measurements and support treatment adjustments.

The role of CGM and AI in diabetes management extends to several potential applications:

• Identifying glucose patterns that require clinical review.
• Supporting remote monitoring and follow-up.
• Improving patient education and self-management.
• Helping care teams identify patients who may need additional support.
• Integrating relevant clinical information to inform treatment discussions.

AI in diabetes management may also support clinical data interpretation, risk identification, and workflow optimization when tools are appropriately validated and supervised.

However, successful adoption depends on data quality, interoperability, affordability, clinician confidence, and appropriate governance. Technology should complement clinical judgment rather than replace it.

For MedTech and digital health companies, these findings provide useful Indian diabetes care market insights into the potential role of connected monitoring and technology-enabled patient support.

5. Diabetes Treatment Access and Affordability Remain Major Barriers

Despite optimism about therapeutic innovation, 58% of surveyed HCPs identified cost, affordability, and access as the greatest implementation barrier.

This finding highlights the importance of diabetes treatment access and affordability in determining whether innovative medicines and monitoring technologies can reach appropriate patients.

Barriers to diabetes treatment access in India may include medication costs, limited insurance coverage, geographic differences in healthcare infrastructure, and the ongoing expenses associated with monitoring and follow-up. The specific contribution of each factor would require additional investigation beyond the current survey.

Potential strategies for pharmaceutical and healthcare technology companies include:

• Developing patient-support and education programs.
• Improving access to appropriate monitoring solutions.
• Generating evidence on clinical and economic value.
• Strengthening partnerships with healthcare providers.
• Designing care pathways suited to different resource settings.

Understanding HCP perspectives on obesity and weight management, treatment costs, and clinical priorities can help companies develop more relevant market access strategies.

6. Future of Diabetes Care in India: HCP Expectations

The study found that 94% of respondents were optimistic or very optimistic about the future of diabetes management over the next decade.

These HCP survey findings on diabetes management suggest confidence in the combined potential of therapeutic innovation, individualized treatment, improved monitoring, and digital technologies.

Three developments are likely to remain important:

Broader outcome-focused treatment: Diabetes treatment decisions will continue to consider glycemic control alongside weight, cardiovascular health, kidney function, and other patient-specific risks.

Greater use of data-enabled care: CGM and digital platforms may support more informed clinical decisions and continuity of care when integrated effectively into healthcare workflows.

Stronger emphasis on access: The real-world impact of new treatments and technologies will depend on affordability, availability, patient suitability, and sustainable implementation.

For healthcare companies, these future trends in diabetes treatment and monitoring create opportunities to align innovation with unmet clinical needs and practical implementation requirements.

Industry Insight: What Diabetes Market Research Means for Pharma and MedTech

The findings from this healthcare professional perception study demonstrate the value of understanding clinical priorities alongside technology and treatment adoption barriers.

For pharmaceutical companies, diabetes market research in India can support medical affairs planning, launch readiness, treatment education, and product positioning. For MedTech providers, it can help identify the monitoring capabilities clinicians value and the implementation challenges they encounter.

Three priorities stand out:

1. Evidence generation: Develop robust clinical and real-world evidence that communicates relevant treatment benefits and limitations.
2. Patient-centered implementation: Account for affordability, adherence, patient preferences, and clinical workflows.
3. Integrated care strategies: Explore how therapies, monitoring technologies, and digital health tools can complement one another.

The study represents the perceptions of 50 HCPs and should be interpreted as directional research rather than a nationally representative assessment of the Indian diabetes market. Additional research across specialties, geographies, and practice settings would help identify differences in treatment priorities and adoption patterns.

Frequently Asked Questions

1. What is a Diabetes HCP Perception Study?

A Diabetes HCP Perception Study examines healthcare professionals' views on diabetes treatment, unmet clinical needs, prescribing considerations, therapeutic innovation, patient access, and emerging healthcare technologies.

2. What are the major unmet needs in diabetes care in India?

Key challenges include sustained glycemic control, treatment adherence, obesity management, cardiometabolic complications, affordability, and access to advanced therapies and monitoring.

3. How are GLP-1 and GIP-based therapies influencing diabetes treatment in India?

These therapies are expanding treatment options by addressing glucose management and, depending on the medicine and patient population, weight management and other clinically relevant outcomes.

4. Why is personalized diabetes treatment important?

Personalized treatment considers individual glycemic needs, cardiovascular and kidney risks, weight-management goals, comorbidities, treatment tolerability, and patient preferences.

5. What is the role of CGM in diabetes management?

CGM provides continuous glucose information and trends that can help appropriate patients and clinicians understand glucose variability and inform treatment decisions.

6. How can AI improve diabetes management?

Validated AI tools may support clinical data analysis, risk identification, workflow efficiency, and targeted follow-up, with appropriate clinical oversight and data governance.

7. What are the main barriers to diabetes treatment access in India?

In this study, 58% of surveyed HCPs identified cost, affordability, and access as the greatest implementation barrier. Further research is needed to assess how individual barriers vary across patient groups and healthcare settings.

8. How can pharmaceutical companies use diabetes market research?

Diabetes market research can inform unmet-need assessment, medical affairs, clinical evidence planning, product positioning, market access, launch strategies, and healthcare professional engagement.

Conclusion

The findings from this Diabetes HCP Perception Study India highlight a healthcare landscape increasingly focused on therapeutic innovation, personalized diabetes treatment, cardiometabolic risk management, and technology-enabled care.

While interest in GLP-1 therapies, CGM, and AI is growing, affordability and access remain central challenges. For pharmaceutical, biotechnology, and MedTech organizations, understanding HCP perceptions is essential to developing evidence-based strategies that reflect clinical realities.

Combining robust healthcare professional insights with accessible treatments, appropriate monitoring, and patient-centered implementation can help stakeholders respond to the evolving needs of diabetes care in India.